U.S. Markets closed
  • S&P 500

    4,109.31
    +58.48 (+1.44%)
     
  • Dow 30

    33,274.15
    +415.12 (+1.26%)
     
  • Nasdaq

    12,221.91
    +208.43 (+1.74%)
     
  • Russell 2000

    1,802.48
    +34.10 (+1.93%)
     
  • Crude Oil

    75.70
    +1.33 (+1.79%)
     
  • Gold

    1,987.00
    -10.70 (-0.54%)
     
  • Silver

    24.24
    +0.25 (+1.03%)
     
  • EUR/USD

    1.0847
    -0.0062 (-0.5640%)
     
  • 10-Yr Bond

    3.4940
    -0.0570 (-1.61%)
     
  • Vix

    18.70
    -0.32 (-1.68%)
     
  • GBP/USD

    1.2332
    -0.0058 (-0.4686%)
     
  • USD/JPY

    132.7970
    +0.1080 (+0.0814%)
     
  • BTC-USD

    28,303.66
    -102.39 (-0.36%)
     
  • CMC Crypto 200

    621.79
    +7.58 (+1.23%)
     
  • FTSE 100

    7,631.74
    +11.31 (+0.15%)
     
  • Nikkei 225

    28,041.48
    +258.55 (+0.93%)
     

Tandem Diabetes Acquires Swiss Based Insulin Patch Pump Developer

  • Tandem Diabetes Care Inc (NASDAQ: TNDM) has agreed to acquire AMF Medical SA, the privately held Swiss developer of the investigational Sigi Patch Pump.

  • It is designed to be an ergonomic, rechargeable patch pump that reduces the burden of managing diabetes through its use of pre-filled insulin cartridges and its compatibility with automated insulin delivery technology.

  • The acquisition expands Tandem's type 1 and type 2 addressable market opportunities.

  • Tandem Diabetes Care will acquire AMF Medical under the following financial terms of the agreement:

  • A previous strategic investment of CHF 8.0 million was paid in Q3 of 2022.

  • A cash payment of CHF 62.4 million is due at closing.

  • Additional contingent earnout payments of up to CHF 129.6 million, in aggregate, are payable upon achieving certain milestones.

  • The transaction is expected to close in January 2023.

  • Price Action: TNDM shares are down 3.40% at $42.16 on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.